Docetaxel in Treating Children With Recurrent Solid Tumors
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00002825|
Recruitment Status : Completed
First Posted : March 1, 2004
Last Update Posted : February 5, 2013
|Condition or disease||Intervention/treatment||Phase|
|Brain and Central Nervous System Tumors Neuroblastoma Sarcoma||Biological: filgrastim Drug: docetaxel||Phase 2|
I. Determine the response rate to docetaxel in children with recurrent sarcomas, neuroblastomas, or brain tumors.
II. Describe the toxic effects of docetaxel in these patients.
All patients receive docetaxel with G-CSF every 21 days for up to 12 courses. Patients are followed for survival.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||20 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A PHASE II STUDY OF DOCETAXEL (TAXOTERE) (NSC# 628503) IN CHILDREN WITH RECURRENT SOLID TUMORS|
|Study Start Date :||January 1997|
|Actual Primary Completion Date :||December 2004|
Experimental: Arm I
All patients receive docetaxel with G-CSF every 21 days for up to 12 courses.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00002825
|Study Chair:||Theodore Zwerdling, MD||University of California, Davis|